Pharma Focus Asia

ALX Oncology Holdings Announces Clinical Trial Collaboration with Sanofi

Wednesday, April 26, 2023

ALX Oncology Holdings announced that it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate evorpacept in combination with SARCLISA (isatuximab-irfc) in patients with multiple myeloma.

This collaboration with Sanofi has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who will benefit from novel effective treatment options. Moreover, collaboration expands robust clinical development pipeline with evorpacept, to establish a new and best-in-class foundational immunotherapy in both haematologic and solid tumours.

Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM.

Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024